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MagnesiumAbstract Background: Paravertebral block is an effective perioperative analgesic modality in
patients undergoing breast or thoracic surgery. Several adjuvants have been reported to improve
the clinical proﬁle of local anaesthetic-induced paravertebral block. In the present study, we
hypothesized that the addition of magnesium sulphate could potentiate the analgesic effects of
paravertebral bupivacaine in female patients undergoing modiﬁed radical mastectomy.
Methods: Ninety female patients ASA physical status 1 and 2 patients scheduled for modiﬁed
radical mastectomy were allocated into 2 groups (45 patients each). Group (B) received bupivacaine
0.25% 0.3 ml/kg in the paravertebral space while group (BM) received 100 mg magnesium
sulphate + bupivacaine 0.25% 0.3 ml/kg in the paravertebral space. Both blocks were done guided
by ultrasound before induction of standard general anaesthetic technique which was the same in
both groups. The two groups were assessed in the ﬁrst post-operative 24 h for post-operative visual
analogue scale (VAS) scores, time to ﬁrst analgesic request, total 24 h morphine consumption,
number of attacks of PONV and any complications from paravertebral block or from the drugs
used in the study.
Results: Patients in group (BM) were found to have reduced VAS scores at 30 min, 2, 4, 6, 12, 24 h
intervals post-operative. The time to ﬁrst analgesic request was longer in patients of group (BM)
with less amount of post-operative opioid consumption and consequently less number of attacks
of PONV in ﬁrst post-operative 24 h. These results were signiﬁcant with a P value < 0.001.
24 M.E. Hassan, E. MahranConclusion: Adding magnesium sulphate to bupivacaine in ultrasound-guided paravertebral block
resulted in more efﬁcient analgesia and opioid-sparing in female patients undergoing modiﬁed
radical mastectomy.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Breast cancer surgery is the most common cancer surgery in
women in the United States [1]. About 40% of breast cancer
surgery patients complain from signiﬁcant acute postoperative
pain [2], and 50% of them develop chronic postoperative pain,
commonly due to inadequate analgesia [3]. Breast surgery is
frequently followed by postoperative nausea and vomiting
(PONV), and restricted movement from pain [4]. One of the
most promising techniques in providing better postoperative
analgesia for breast cancer surgery patients is the paravertebral
block (PVB) [5]. It is associated with better control of postop-
erative pain, less opioids requirement for postoperative analge-
sia, decrease in postoperative nausea and vomiting (PONV),
reduced postoperative pulmonary complications and better
patient outcome [5]. It was also reported that paravertebral
block decreases chronic postoperative pain and improves
wound subcutaneous oxygenation which leads to better wound
healing and less risk of infection [6,7].
Several adjuvants as fentanyl and clonidine have been
reported to improve the clinical proﬁle of paravertebral block
in breast surgery but addition of these adjuvants was associ-
ated with more adverse effects as hypotension and vomiting
[8]. Paravertebral clonidine was also found to have a sedative
effect [9]. Hence the need to try another adjuvant with better
analgesic proﬁle and with less adverse effects.
Magnesium is a competitiveNMDA(N-methylD-aspartate)
receptors antagonist. NMDA receptors are excitatory amino
acid receptors which are activated by various excitatory amino
acid neurotransmitters such as glutamate and aspartate in
response to painful stimuli. Activation of NMDA receptors
leads to calcium inﬂux into the cells, the action which can be
blocked by magnesium [10]. Calcium inﬂux leads to a series of
central sensitization such as wind-up phenomenon and long
term potentiation which are important mechanisms that
determine the duration and intensity of post-operative pain,
hence the role of magnesium as a NMDA receptors antagonist
in the prevention of these cascades of reactions leading to
reduced post-operative pain [11].
The mechanism of analgesic action of magnesium when
injected in paravertebral space where the spinal nerves and
posterior rami pass is still unclear. Theories about how magne-
sium exerts its action in paravertebral space may be systemic
effect, epidural spread or direct action on the peripheral
nerves. Systemic effect can be excluded as the dose of magne-
sium used in our study was a small dose and it was likely to be
too low to produce a systemic effect or to pass through blood
brain barrier. Also epidural spread is uncertain due to the
absence of epidural side effects of local anaesthetic as hypoten-
sion. So the mechanism is likely the direct action of magnesium
on the peripheral nerve by blocking the release of excitatory
neurotransmitter at the synaptic junction or by potentiating
the effect of local anaesthetic [12].Magnesium has been used as an adjuvant to local anaes-
thetics in thoracic surgery and was found to improve analgesic
efﬁcacy [13]. The analgesic efﬁcacy of magnesium in local
anaesthetic-induced paravertebral block was not tried before
in breast surgery.
We designed this study to evaluate the effect of magnesium
sulphate as an adjuvant in potentiating the analgesic effect of
bupivacaine in paravertebral block in breast cancer surgeries.
2. Patients and methods
After obtaining approval from the local Ethics Committee and
written informed consent, 90 female ASA physical status 1 and
2 patients scheduled for modiﬁed radical mastectomy were
enrolled in this study. This study was carried out at National
Cancer Institute – Cairo University. The exclusion criteria
were local infection at the site of the block, coagulation
disorders, body mass index > 35, allergy to local anaesthetics
or magnesium sulphate, patient refusal, severe respiratory or
cardiac disorders, pre-existing neurological deﬁcits, liver or
renal insufﬁciency, pregnancy, breast reconstruction surgery,
bilateral breast surgery, kyphoscoliosis, presence of acute
herpes zoster, chronic pain syndrome, chronic analgesic use
and psychiatric disease.
During the pre-anaesthetic assessment visit patients were
educated about reporting pain on the 11-point visual
analogue scale (VAS), where 0 = no pain and 10 = worst
imaginable pain, and were also educated how to use the
patient-controlled analgesia pump.
On arrival to the operating room, basic monitoring was
initiated using non-invasive blood pressure measurements,
continuous electrocardiography and pulse oximetry. Before
induction of general anaesthesia, all patients received ultra-
sound-guided (US) thoracic paravertebral block (TPVB). The
scanning probe was linear multi-frequency 13–16 MHz probe.
The patients were sedated with midazolam 2 mg i.v. to relieve
anxiety and provide comfort during the block. The patients
were placed in the lateral position with the side of the surgery
upwards. The site of paravertebral block was sterilized using
iodine solution, and the ultrasound probe was covered by a
disposable sterile cover.
After location of the paravertebral space by US, a 26-gauge
needle was inserted 2.5 cm lateral to the cephalic edge of
the fourth thoracic vertebral spinal process and skin and sub-
cutaneous tissue were anaesthetized with 5 ml of lidocaine
20 mg/ml. High frequency linear ultrasound (U/S) probe was
used to locate the paravertebral space and a 18 G Touhy
needle was inserted perpendicular to hit the transverse process
by an out-of-plane approach. After hitting this bony structure,
the needle was redirected cephalic at 15 towards the
paravertebral space. After localization of the needle in
the paravertebral space and negative aspiration, injection of
the medication prepared for each group of the study was
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conﬁrmed by expansion of the paravertebral space between
the pleura and the superior costo-transverse ligament [14].
Patients were allocated to one of two groups of 45 patients
each using a computer-generated random numbers concealed
in sealed opaque envelopes. Group (B): received bupivacaine
0.25% 0.3 ml/kg in the paravertebral space. Group (BM):
received 100 mg magnesium sulphate + bupivacaine 0.25%
0.3 ml/kg in the paravertebral space.
Success of the block was evaluated using the pinprick test
within 30 min after the block. Failure of adequate paraverte-
bral block was considered if evident loss of pinprick discrimi-
nation was delayed more than 30 min in dermatomes (T2–T6).
Patients with failed block were excluded from the study. A
staff anaesthesiologist not involved in the management of the
patient or study prepared the paravertebral medication accord-
ing to randomization. The patients and all staff involved in
patient management and data collection were unaware of the
group assignment.
General anaesthesia was induced using fentanyl 2 lg/kg i.v.
and propofol 2 mg/kg and rocuronium 0.6 mg/kg to facilitate
endotracheal intubation. Anaesthesia was maintained with
sevoﬂurane with MAC 2–2.5%. Supplemental doses of rocuro-
nium 0.1 mg/kg i.v. were administered as required to maintain
muscle relaxation during surgery guided by peripheral nerve
stimulator. The tidal volume was set at 8–10 ml/kg and respi-
ratory frequency was adjusted to maintain end tidal CO2 at 30
and 35 mmHg. Additional doses of fentanyl 1 lg/kg i.v. were
given if heart rate and mean arterial blood pressure (MAP)
increased more than 20% from the pre-operative baseline.
Metoclopramide 10 mg i.v. was given 10 min before the end
of the surgery. At the end of surgery, neuromuscular blockade
was reversed with neostigmine 0.05 mg/kg and atropine
0.02 mg/kg and extubation was done after full return of
consciousness.
After recovery from anaesthesia, the patients were
transferred to the post-operative recovery room, and a patient
controlled intravenous analgesia (PCA) device was ready to be
connected on ﬁrst request to postoperative analgesia. The PCA
device was set to all groups with a demand dose of 1 mg
morphine and a lockout interval of 10 min and without a
continuous background infusion [15].
All patients were assessed for the following parameters:
Pain: Visual analogue scale (VAS) score was used to assess
the pain scores in the patient by a blinded observer both at rest
and on movement of the shoulder at 30 min and subsequently
2, 4, 6, 12, and 24 h after the recovery.
Time till the ﬁrst analgesic requirement: which was the time
interval from recovery of the patient from anaesthesia till time
of his ﬁrst analgesic request.
Total PCA morphine consumption during the ﬁrst
postoperative 24 h.
PONV: was assessed as number of attacks of nausea or
vomiting in the ﬁrst 24 h after surgery and metoclopramide
10 mg i.v. was given for every attack of nausea or vomiting.
The patients were evaluated for any other complications or
side effects up to 24 h after the surgery.
Sample size estimation was based on the non-parametric
distribution of VAS score with a signiﬁcance of (a= 0.05)
and power (1  b= 0.80). The primary outcome measure
was VAS score at rest 4 h post-operative. The expected reduc-
tion in VAS score 4 h post-operative was 0.53 and the expectedvariability (standard deviation) was 0.7. Mann–Whitney U test
as a model was used for calculating the number needed per
group based on previous knowledge of an average VAS score
of pain after 24 h with Mg + local anaesthesia in epidural
space of 1.6 ± 0.7 [16] compared to 2.13 ± 0.64 in group
receiving paravertebral local anaesthesia [17]. The minimum
number of patients was calculated as 40 per group. To com-
pensate for possible drop-outs we increased the number to
45 for each group.
2.1. Statistical methods
Statistical Package for Social Sciences (SPSS) version 17.0 was
used for data analysis. Mean ± standard deviation was used
for the description of VAS scores, time to ﬁrst analgesic
requirement and total 24 h morphine consumption. Median
and range was used for the description of attacks of vomiting.
Parametric and non-parametric independent t test compared
mean and medians of the 2 study groups. P values were set sig-
niﬁcant at 0.05 level.3. Results
The present study showed no signiﬁcant difference between the
2 groups as regards demographic data (Table 1).
Addition of magnesium sulphate to bupivacaine 0.25% in
the paravertebral space signiﬁcantly reduced VAS scores at
all time assessment points, both at rest and with shoulder
movement (Table 2).
The times to ﬁrst analgesic request after surgery were
547.8 ± 69.2 and 283.4 ± 77.0 min in group (BM) and group
(B), respectively (P< 0.001). Furthermore, patients in group
(BM) required less amount of morphine in the ﬁrst 24 h of
postoperative period (15.9 ± 3.1 mg) compared to the control
bupivacaine group (23.2 ± 3.7 mg) with p-value < 0.001.
The median number of attacks of PONV in patients in
group (BM) in the ﬁrst 24 h after surgery was 0 with range
(0–2) which was lower than that of patients in group (B) whose
median was 1 and range was (0–3). Less number of patients (12
patients) in the bupivacaine magnesium sulphate group (BM)
required metoclopramide as a rescue antiemetic compared to
the number of patients in the bupivacaine group (B) which
was 25 patients (P= 0.001).
Patients of both groups were observed for other complica-
tions as respiratory depression, drowsiness and pruritis. None
of these complications was reported by the patients of the
present study. Complications related to paravertebral block
technique, as epidural spread denoted by hypotension, were
absent.4. Discussion
The results of the present study demonstrated that the addition
of magnesium sulphate to ultrasound-guided, bupivacaine-
induced paravertebral block improves postoperative pain
scores and reduces postoperative PCA morphine consumption
and opioid-induced side effects in female patients undergoing
modiﬁed radical mastectomy.
The direct action of magnesium on the peripheral nerves is
supported by the study done by Belgin Buyukakilli et al. [18],
Table 1 Demographic data in both groups. Values are means (SD).
Group (BM) (n= 45) Group (B) (n= 45) P-value
Age (years) 55.1 ± 9.8 55.0 ± 10.3 0.96
Weight (kg) 70.7 ± 8.2 71.4 ± 7.2 0.68
Height (cm) 163.5 ± 5.9 164.7 ± 6.0 0.36
Duration of surgery (min) 125.2 ± 19.2 128.6 ± 18.7 0.43
*P value is signiﬁcant 6 0.05.
Group (B) = Control bupivacaine group, Group (BM) = Combined magnesium sulphate and bupivacaine group.
Table 2 Visual analogue scores at rest and with movement. Values are means (SD).
Group (BM) (n= 45) Group (B) (n= 45) P-value
VAS-R 30 min 1.2 ± 0.93 2.6 ± 0.59 <0.001
VAS-M 30 min 3.4 ± 0.95 5.1 ± 1.02 <0.001
VAS-R 2 h 1.5 ± 0.93 2.6 ± 0.54 <0.001
VAS-M 2 h 3.5 ± 1.0 5.5 ± 0.87 <0.001
VAS-R 4 h 1.6 ± 0.81 3.4 ± 0.98 <0.001
VAS-M 4 h 3.1 ± 0.9 5.1 ± 1.20 <0.001
VAS-R 6 h 1.9 ± 0.73 3.4 ± 0.93 <0.001
VAS-M 6 h 3.2 ± 0.82 5.0 ± 1.08 <0.001
VAS-R 12 h 1.3 ± 0.75 2.7 ± 1.13 <0.001
VAS-M 12 h 2.7 ± 1.06 4.2 ± 1.13 <0.001
VAS-R 24 h 1.3 ± 0.62 2.2 ± 0.83 <0.001
VAS-M 24 h 2.8 ± 0.74 4.0 ± 1.08 <0.001
* P value is signiﬁcant 6 0.05.VAS-R: visual analogue scale at rest.VAS-M: visual analogue scale with movement.
Group (B) = Control bupivacaine group, Group (BM) = Combined magnesium sulphate and bupivacaine group.
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better impulse inhibition in a frog sciatic nerve. This was in
agreement with what Goyal et al. found in their study [19].
They found that administration of a small dose of magnesium
only in the axillary sheath during brachial plexus analgesia
resulted in prolonged time of post-operative pain relief with
reduction of post-operative analgesic requirement and without
any major side effects.
The efﬁcacy of adding magnesium to bupivacaine in para-
vertebral block to control post-operative pain in thoracic sur-
gery is evaluated in a study done by Ammar and Mahmoud
[13]. The results of their study was in agreement with that of
our study and this agreement support the good analgesic efﬁ-
cacy of adding magnesium as an adjuvant to bupivacaine in
paravertebral block.
Absence of complications related to the paravertebral block
technique as pneumothorax and epidural spread may be due to
the use of ultrasound guided technique which allows better
localization of the needle in the paravertebral space [20].
Expansion of the paravertebral space and displacement of
the pleura by the injected medications was an additional sure
sign of a good and safe site of the tip of the needle, which min-
imize the risk of pleural puncture [21].
This study has some limitations: (1) postoperative assess-
ment duration was limited for 24 h. Probably an extended
48–72 h observation period will be more informative, and (2)
we have evaluated one relatively small dose level of magnesium
sulphate to minimize the possible confounding effects of sys-
temic absorption. However, future studies should consider
investigating different dose levels of magnesium sulphate to
ﬁnd out the appropriate safe dose associated with the maxi-
mum extension in the duration of paravertebral analgesia.5. Conclusion
In brief, the results of improved and prolonged analgesia with
less opioid related side effects in our study revealed that adding
of magnesium sulphate to bupivacaine can improve the clinical
proﬁle of ultrasound-guided thoracic paravertebral block in
patients undergoing modiﬁed radical mastectomy.
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